CBD as potential treatment for Alzheimer’s disease

Interesting extract from a medical journal I was reading about CBD as treatment for memory performance. You'll need to read the original article for all the academic citations. Extract follows:

Among the various functions of cannabidiol are anti-inflammatory properties, demonstrated in vitro and in vivo (in rats) (Cassano et al. 2020; Esposito et al. 2011) and antioxidant properties in vitro. Additionally, CBD was found to inhibit the hyperphosphorylation of tau proteins in vitro, which, as mentioned, is present in AD human patients and in some FCD patients. CBD has also been shown to increase the cerebral blood flow in vivo (in mouse models after stroke), attenuate the neurotoxicity of the β-amyloid protein accumulation in vitro and in vivo (in mice), modulate microglial cell function, and reverse cognitive deficits in transgenic animal models (in mice). Thus, CBD has the potential to counter many of the pathological processes in AD. 

A published case communication demonstrated treatment of an 81-year-old man that suffered from dementia after several cardiovascular events and presented with drowsiness, difficulty keeping his eyes open, inability to maintain eye contact for more than a few seconds, inability to speak, difficulties to communicate, and severe spasticity. He was treated with CBD, starting with 3 daily drops of CBD oil and after approximately 7 days the dose was increased to 4 daily drops of CBD oil. A few days after commencing treatment, his alertness and responsiveness improved and he was able to say a few words. A month after beginning the treatment, he remained more alert and responsive, continued to say a few words, and regained his ability to make eye contact for more than a few seconds, and his spasticity decreased. No side effects were reported.


Classic animal models fail to predict the outcome of new treatments more than they succeed. This causes inefficient use of resources and compromises animal welfare without promoting human or animal health. We suggest, in accord with the One Health Initiative, that a better model for human disease can be found in domestic pets, with naturally occurring diseases who share the human environment so the disease mechanisms and features have a higher chance of simulating the human equivalent. Moreover, we suggest that these trials should be conducted as clinical veterinary trials to develop treatment for the parallel conditions in domestic pets, thus enhancing animal welfare, promoting better veterinary care, and saving resources by simultaneously developing treatments for humans and pets. We find feline cognitive dysfunction a promising model for human Alzheimer’s disease. Therefore, we suggest that conducting a clinical trial in aging domestic cats, for researching the benefits of CBD for both conditions, can promote the treatment of these two difficult conditions in humans and pets.